Optimal Antiplatelet Regimen in Bi-Risk ACS?

The large OPT-BIRISK trial adds important information to the complex puzzle of antithrombotic therapy after PCI for acute coronary syndrome, says one expert.

Related Keywords

North Carolina ,United States ,China ,Shenyang ,Liaoning ,Amsterdam ,Noord Holland ,Netherlands ,Duke University ,American ,Renatod Lopes ,Yaling Han ,Academic Research Consortium ,European Society Of Cardiology ,General Hospital ,Northern Theater Command ,European Society ,East Asian ,Medscape Cardiology ,American Heart Journal ,Bleeding Academic Research Consortium ,Low Risk Subset ,Bi Risk Patients ,Commonly Seen ,Acute Coronary Syndrome Acs ,Cute Coronary Syndrome ,Cs ,Thromboembolism ,Antiplatelet Agent ,Aspirin ,Stroke ,Erebrovascular Accident ,Va Cerebrovascular Accident ,Angina ,Angina Pectoris ,Antithrombotics ,Anti Thrombotics ,Antithrombotic Therapy ,Antithrombotic Agents ,Hemorrhage ,Bleeding ,Chronic Renal Failure ,Hronic Kidney Failure ,Hronic Kidney Disease Ckd ,Chronic Kidney Disease ,Kd ,D ,